Cell therapy for pancreatic cancer: MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy

Yoshinari Maeda; Shoichi Hazama; Shin Yoshida; Kazunari Maeda; Yuka Sonoda; Yuko Yanai; Kiyoshi Yoshimura; Michihisa Iida; Nobuaki Suzuki; Tomio Ueno; Shigefumi Yoshino; Masaaki Oka

Cell therapy for pancreatic cancer: MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy

Yoshinari Maeda, Shoichi Hazama, Shin Yoshida, Kazunari Maeda, Yuka Sonoda, Yuko Yanai, Kiyoshi Yoshimura, Michihisa Iida, Nobuaki Suzuki, Tomio Ueno, Shigefumi Yoshino, Masaaki Oka

Research output: Contribution to journal › Article › peer-review

Abstract

MUC1 is a tumor-associated antigen that is overexpressed in invasive ductal carcinomas of the pancreas (PC). MUC1-specific cytotoxic T lymphocytes (CTLs) recognize MUC1 molecules in an HLA-unrestricted manner. We have reported the efficacy of adoptive immunotherapy (AIT) with CTLs stimulated by autologous pancreatic tumors and vaccination with a variety of peptides. We also have reported the use of AIT with CTLs (MUC1-CTLs)stimulated by an MUC1-expressing human pancreatic cancer cell line, YPK-1. AIT with MUC1-CTLs for unresectable pancreatic cancer did not improve survival, although no patient without liver metastasis developed liver metastasis during the study. To overcome these limitations, we developed an AIT using a combination of MUC1-CTLs and dendritic cells (DCs) pulsed with MUC1-peptide. This AIT showed good results. In our next study, we are planning AIT with MUC1-CTLs and DCs transfected with MUC1-mRNA for unresectable PC.

Original language	English (US)
Pages (from-to)	105-110
Number of pages	6
Journal	Biotherapy
Volume	24
Issue number	2
State	Published - Mar 2010
Externally published	Yes

Keywords

Bectroporation
Immunotherapv
MUC1
Pancreatic cancer

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

Fingerprint Dive into the research topics of 'Cell therapy for pancreatic cancer: MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy'. Together they form a unique fingerprint.

Cite this

Cell therapy for pancreatic cancer : MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy. / Maeda, Yoshinari; Hazama, Shoichi; Yoshida, Shin; Maeda, Kazunari; Sonoda, Yuka; Yanai, Yuko; Yoshimura, Kiyoshi; Iida, Michihisa; Suzuki, Nobuaki; Ueno, Tomio; Yoshino, Shigefumi; Oka, Masaaki.

In: Biotherapy, Vol. 24, No. 2, 03.2010, p. 105-110.

Research output: Contribution to journal › Article › peer-review

Maeda, Yoshinari ; Hazama, Shoichi ; Yoshida, Shin ; Maeda, Kazunari ; Sonoda, Yuka ; Yanai, Yuko ; Yoshimura, Kiyoshi ; Iida, Michihisa ; Suzuki, Nobuaki ; Ueno, Tomio ; Yoshino, Shigefumi ; Oka, Masaaki. / Cell therapy for pancreatic cancer : MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy. In: Biotherapy. 2010 ; Vol. 24, No. 2. pp. 105-110.

@article{bd347e877bae4916b387d377ad41815a,

title = "Cell therapy for pancreatic cancer: MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy",

abstract = "MUC1 is a tumor-associated antigen that is overexpressed in invasive ductal carcinomas of the pancreas (PC). MUC1-specific cytotoxic T lymphocytes (CTLs) recognize MUC1 molecules in an HLA-unrestricted manner. We have reported the efficacy of adoptive immunotherapy (AIT) with CTLs stimulated by autologous pancreatic tumors and vaccination with a variety of peptides. We also have reported the use of AIT with CTLs (MUC1-CTLs)stimulated by an MUC1-expressing human pancreatic cancer cell line, YPK-1. AIT with MUC1-CTLs for unresectable pancreatic cancer did not improve survival, although no patient without liver metastasis developed liver metastasis during the study. To overcome these limitations, we developed an AIT using a combination of MUC1-CTLs and dendritic cells (DCs) pulsed with MUC1-peptide. This AIT showed good results. In our next study, we are planning AIT with MUC1-CTLs and DCs transfected with MUC1-mRNA for unresectable PC.",

keywords = "Bectroporation, Immunotherapv, MUC1, Pancreatic cancer",

author = "Yoshinari Maeda and Shoichi Hazama and Shin Yoshida and Kazunari Maeda and Yuka Sonoda and Yuko Yanai and Kiyoshi Yoshimura and Michihisa Iida and Nobuaki Suzuki and Tomio Ueno and Shigefumi Yoshino and Masaaki Oka",

year = "2010",

month = mar,

language = "English (US)",

volume = "24",

pages = "105--110",

journal = "Biotherapy",

issn = "0914-2223",

publisher = "Japanese Society for Cancer Chemotherapy",

number = "2",

}

TY - JOUR

T1 - Cell therapy for pancreatic cancer

T2 - MUC1-specific cytotoxic T cell and MUC1 mRNA introduction dendritic cell therapy

AU - Maeda, Yoshinari

AU - Hazama, Shoichi

AU - Yoshida, Shin

AU - Maeda, Kazunari

AU - Sonoda, Yuka

AU - Yanai, Yuko

AU - Yoshimura, Kiyoshi

AU - Iida, Michihisa

AU - Suzuki, Nobuaki

AU - Ueno, Tomio

AU - Yoshino, Shigefumi

AU - Oka, Masaaki

PY - 2010/3

Y1 - 2010/3

N2 - MUC1 is a tumor-associated antigen that is overexpressed in invasive ductal carcinomas of the pancreas (PC). MUC1-specific cytotoxic T lymphocytes (CTLs) recognize MUC1 molecules in an HLA-unrestricted manner. We have reported the efficacy of adoptive immunotherapy (AIT) with CTLs stimulated by autologous pancreatic tumors and vaccination with a variety of peptides. We also have reported the use of AIT with CTLs (MUC1-CTLs)stimulated by an MUC1-expressing human pancreatic cancer cell line, YPK-1. AIT with MUC1-CTLs for unresectable pancreatic cancer did not improve survival, although no patient without liver metastasis developed liver metastasis during the study. To overcome these limitations, we developed an AIT using a combination of MUC1-CTLs and dendritic cells (DCs) pulsed with MUC1-peptide. This AIT showed good results. In our next study, we are planning AIT with MUC1-CTLs and DCs transfected with MUC1-mRNA for unresectable PC.

AB - MUC1 is a tumor-associated antigen that is overexpressed in invasive ductal carcinomas of the pancreas (PC). MUC1-specific cytotoxic T lymphocytes (CTLs) recognize MUC1 molecules in an HLA-unrestricted manner. We have reported the efficacy of adoptive immunotherapy (AIT) with CTLs stimulated by autologous pancreatic tumors and vaccination with a variety of peptides. We also have reported the use of AIT with CTLs (MUC1-CTLs)stimulated by an MUC1-expressing human pancreatic cancer cell line, YPK-1. AIT with MUC1-CTLs for unresectable pancreatic cancer did not improve survival, although no patient without liver metastasis developed liver metastasis during the study. To overcome these limitations, we developed an AIT using a combination of MUC1-CTLs and dendritic cells (DCs) pulsed with MUC1-peptide. This AIT showed good results. In our next study, we are planning AIT with MUC1-CTLs and DCs transfected with MUC1-mRNA for unresectable PC.

KW - Bectroporation

KW - Immunotherapv

KW - MUC1

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=77951541226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951541226&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77951541226

VL - 24

SP - 105

EP - 110

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 2

ER -